Jonathan Gerber, MD of Levine Cancer Institute, gives an overview of a clinical study that shows pembrolizumab is active in relapsed refractory populations of AML at the 58th ASH Annual Meeting in San Diego, CA.
Study Shows Pembrolizumab Active in Relapsed Refractory Populations
